z-logo
Premium
Samidorphan, recently Schedule II, approved as psychiatric combo
Author(s) -
Knopf Alison
Publication year - 2021
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.33097
Subject(s) - olanzapine , food and drug administration , psychiatry , schizophrenia (object oriented programming) , medicine , schedule , bipolar disorder , psychology , pharmacology , lithium (medication) , management , economics
This month, the Food and Drug Administration (FDA) approved samidorphan and olanzapine, a new combination medication, for the treatment of schizophrenia and bipolar disorder. The medication sponsor is Alkermes, and the medication is called Lybalvi.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here